World Investment Advisors Grows Position in Merck & Co., Inc. $MRK

World Investment Advisors boosted its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 29.6% during the 4th quarter, Holdings Channel reports. The firm owned 87,754 shares of the company’s stock after acquiring an additional 20,067 shares during the quarter. World Investment Advisors’ holdings in Merck & Co., Inc. were worth $9,237,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently bought and sold shares of MRK. D.A. Davidson & CO. boosted its holdings in Merck & Co., Inc. by 4.4% during the fourth quarter. D.A. Davidson & CO. now owns 576,959 shares of the company’s stock worth $60,731,000 after buying an additional 24,576 shares in the last quarter. Farther Finance Advisors LLC boosted its holdings in Merck & Co., Inc. by 48.9% during the fourth quarter. Farther Finance Advisors LLC now owns 97,818 shares of the company’s stock worth $10,296,000 after buying an additional 32,114 shares in the last quarter. Coldstream Capital Management Inc. raised its position in Merck & Co., Inc. by 12.7% during the third quarter. Coldstream Capital Management Inc. now owns 123,366 shares of the company’s stock worth $10,364,000 after acquiring an additional 13,940 shares during the period. NEOS Investment Management LLC raised its position in Merck & Co., Inc. by 39.9% during the third quarter. NEOS Investment Management LLC now owns 347,684 shares of the company’s stock worth $29,181,000 after acquiring an additional 99,074 shares during the period. Finally, Campbell Capital Management Inc. acquired a new position in Merck & Co., Inc. during the third quarter worth $1,866,000. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Analysts and market commentary highlighted that Keytruda drove Merck’s strong first-quarter sales, with revenue topping expectations and sales around $8 billion, reinforcing the drug’s importance to MRK’s 2026 growth outlook. Article Title
• Positive Sentiment: Merck said it will present new long-term oncology data and more than 100 abstracts at ASCO 2026, which could keep investor focus on the strength of its cancer portfolio and pipeline. Article Title
• Positive Sentiment: Merck broadened KEYTRUDA collaboration efforts with partners including Erasca and Inhibrx, signaling continued pipeline development around combination therapies as the company prepares for eventual patent-expiry pressure. Article Title
• Neutral Sentiment: One analyst reinstated Merck with a “Neutral” rating and a $125 price target, suggesting the stock may be fairly valued near current levels rather than clearly undervalued or overvalued. Article Title
• Neutral Sentiment: A valuation-focused article noted mixed recent share performance, including short-term weakness despite strong longer-term returns, which may be tempering enthusiasm even as fundamentals remain solid. Article Title

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. Guggenheim upped their price objective on shares of Merck & Co., Inc. from $122.00 to $140.00 and gave the stock a “buy” rating in a research report on Friday, February 6th. Deutsche Bank Aktiengesellschaft upgraded shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $150.00 price objective for the company in a research report on Friday, February 13th. UBS Group upped their price objective on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a “buy” rating in a research report on Monday, April 13th. Citigroup assumed coverage on shares of Merck & Co., Inc. in a research report on Wednesday, May 6th. They set a “neutral” rating and a $125.00 price objective for the company. Finally, Cantor Fitzgerald upped their price objective on shares of Merck & Co., Inc. from $116.00 to $120.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 4th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and seven have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $128.18.

Merck & Co., Inc. Stock Performance

NYSE:MRK opened at $113.57 on Thursday. The company has a fifty day moving average of $116.31 and a two-hundred day moving average of $109.01. The stock has a market capitalization of $280.49 billion, a PE ratio of 31.99, a P/E/G ratio of 2.53 and a beta of 0.18. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30. Merck & Co., Inc. has a fifty-two week low of $73.31 and a fifty-two week high of $125.14.

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.19. The business had revenue of $16.29 billion during the quarter, compared to analysts’ expectations of $15.85 billion. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The company’s quarterly revenue was up 4.9% compared to the same quarter last year. During the same period in the prior year, the business earned $2.22 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. As a group, research analysts forecast that Merck & Co., Inc. will post 5.16 earnings per share for the current fiscal year.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.